
Jury Awards USD 8 Million to Illumina in Patent Fight with BGI
shot by IP News Shots / 6:38 pm on 03 December, 2021
A federal jury at the U.S. District Court for the Northern District of California ruled in favour of Illumina, Inc. in DNA patent infringement fight with BGI Genomics (currently known as BGI Group). The jury found Illumina’s four out of five patent valid and also awarded USD 8 million.
Industry: Biotechnology | News Category: Litigations | Type of IP: Patent
Read more at Law360
PTAB Agrees to Pfizer’s Request to Review UniQure Hemophilia Patent
shot by IP News Shots / 4:42 pm on 22 November, 2021
The Patent Trial and Appeal Board (PTAB) has acknowledged Pfizer, Inc.’s plea to review two gene therapy patents owned by UniQure Biopharma B.V. Pfizer has asserted that patents do not contain new ideas and should be cancelled. PTAB agreed with Pfizer in three separate decisions.
Industry: Biotechnology, Pharmaceuticals | News Category: Litigations | Type of IP: Patent
Read more at Bloomberg Law
Onyx Drops Patent Lawsuit over Cancer Drug Nexavar against Dr. Reddy’s Lab
shot by IP News Shots / 4:32 pm on 22 November, 2021
Onyx Pharmaceuticals, Inc., a subsidiary of Amgen, Inc., and Bayer Healthcare, LLC has agreed to dismiss their patent infringement litigation against Dr. Reddy’s Laboratories, Inc. in the U.S. District Court for the District of Delaware. Onyx and Bayer accused Dr. Reddy’s over the generic version of Nexavar, a cancer drug used in the treatment of liver, kidney and thyroid cancer. The parties have discarded the case with prejudice, i.e., there will be no further litigation.
Industry: Biotechnology, Pharmaceuticals | News Category: Litigations | Type of IP: Patent
Read more at Reuters
Alterola Biotech Acquires Assets and IP from C2 Wellness
shot by IP News Shots / 7:32 pm on 17 November, 2021
Alterola Biotech Inc. declared that it is purchasing assets from C2 Wellness Corporation. The scientific team of C2 invents and develops certain platform technologies and associated intellectual property (IP). Alterola purchased C2 for USD 12 million. The board of both the companies has agreed to the execution of the transaction. The assets will also comprise relationships with universities and numerous renowned academics along with the technology platforms and associated intellectual property.
Industry: Biotechnology, Pharmaceuticals | News Category: Deals - Acquisitions | Type of IP: All
Read more at Guru Focus
Amgen Supports Juno’s Effort to Restore USD 1.1 Billion Patent Judgement
shot by IP News Shots / 8:53 pm on 15 November, 2021
Amgen, Inc. has backed cancer research centers to support Juno Therapeutics, Inc. a subsidiary of Bristol-Myers Squibb to reinstate a USD 1.1 billion patent verdict against Kite Pharma, Inc. that was discarded by the U.S. Court of Appeals for the Federal Circuit (CAFC). Amgen stated that the verdict has fuelled uncertainty for obtaining pharmaceutical and biotech patents.
Industry: Biotechnology, Pharmaceuticals | News Category: Litigations | Type of IP: Patent
Read more at Law360
California Jury Empaneled for Illumina and BGI’s Patent Lawsuit
shot by IP News Shots / 8:50 pm on 15 November, 2021
The U.S. District Court for the Northern District of California judge empaneled a nine-member jury to take up an unbiased decision in a patent infringement lawsuit between Illumina, Inc. and BGI Genomics Co., Ltd. Illumina has accused BGI for infringing five patents related to DNA sequencing.
Industry: Biotechnology | News Category: Litigations | Type of IP: Patent
Read more at Law360